HELP NASDAQ
Helus Pharma Inc.
1W: -3.1%
1M: -17.8%
3M: +36.3%
YTD: +25.1%
1Y: +72.7%
3Y: -46.4%
5Y: -86.0%
$10.52
+0.16 (+1.54%)
After Hours: $10.55 (+0.03, +0.29%)
Weekly Expected Move ±9.0%
$8
$9
$10
$11
$12
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 8.81.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Moderate
50
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$642.2M
52W Range3.76-15.15
Volume1,032,945
Avg Volume1,754,789
Beta0.54
Dividend—
Analyst Ratings
Company Info
CEOMichael I. Halstead
Employees100
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2019-09-13
Websitehelus.com
100 King Street West, Suite 5600
Toronto, ON M5X 1C9
CA
Toronto, ON M5X 1C9
CA
908 764 8385
About Helus Pharma Inc.
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
Latest News
Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
FDA names acting heads of drug and vaccine units to permanent roles
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Inamdar Amir | 0 | — | 2026-10-13 | |
| Inamdar Amir | 0 | — | 2026-10-13 | |
| Inamdar Amir | 66,668 | — | 2026-10-13 | |
| Lewis-Hall Freda C | 0 | — | 2026-10-13 | |
| Lewis-Hall Freda C | 25,000 | $5.99 | 2026-10-13 |